Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocytes.

Cryopreserved and thawed lymphocytes can be used instead of fresh lymphocytes to avoid test-to-test variability in studies of fluctuations of natural killer (NK) and lymphokine-activated killer (LAK) activities as a function of time. We investigated the effects of 1-h versus 18-h resting of lymphocytes on their lytic activities, because the process of cryopreservation and thawing decreases NK and LAK activities. Lymphocytes from renal cell cancer patients receiving adoptive immunotherapy were studied. An 18-h versus 1-h resting period led to a significant increase in NK activity but had no significant effect on LAK activity. The presence of 1200 IU/ml interleukin 2 (IL-2) in the medium 1 h prior to and during the cytotoxicity (CTX) assay increased in vivo and in vitro IL-2-induced LAK activities. This phenomenon has been interpreted as IL-2 dependency of effector lymphocytes (J.A. Hank, P.C. Kohler, G. Weil-Hillman, N. Rosenthal, K. H. Moore, B. Storer, D. Minkoff, J. Bradshaw, R. Bechhofer, and P. M. Sondel. Cancer Res., 48: 1965-1971, 1988). We performed kinetic studies to assess the role of effector lymphocyte recruitment in these experiments. LAK activity was tested in the presence or absence of IL-2 during preincubations and CTX assays varying between 0 and 120 min. These kinetic studies showed that effector lymphocyte recruitment indeed contributed to the increased level of LAK activity when IL-2 was added to the CTX assay. A minimal incubation period of 30 min was required to detect recruitment of lymphocytes. Effector lymphocytes could be recruited for periods varying between 90 and greater than 240 min, depending on the lymphocyte donor. We conclude that: (a) in vitro, IL-2-mediated recruitment of lymphocytes due to presence of IL-2 in the CTX assay may lead to an overestimate of the actual LAK activity; and (b) in vivo, prolonged IL-2 infusion after the administration of activated lymphocytes seems warranted in order to recruit maximal levels of effector lymphocytes with LAK activity.

[1]  I. Schmidt-Wolf,et al.  Lymphokine-activated killer cell activity after cryopreservation. , 1989, Journal of immunological methods.

[2]  S. Fosså,et al.  Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study. , 1989, European journal of cancer & clinical oncology.

[3]  W. Linehan,et al.  Experience with the Use of High‐Dose Interleukin‐2 in the Treatment of 652 Cancer Patients , 1989, Annals of surgery.

[4]  A. Komiyama,et al.  Induction of lymphokine‐activated killer and natural killer cell activities from cryopreserved lymphocytes , 1988, Transfusion.

[5]  T. Eberlein,et al.  Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells. , 1988, Cancer research.

[6]  R. Bechhofer,et al.  In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2. , 1988, Cancer research.

[7]  R. Bechhofer,et al.  The in vitro function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2. , 1988, Journal of biological response modifiers.

[8]  L. Lanier,et al.  In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  W. M. Linehan,et al.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.

[10]  G. Marshall,et al.  Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. , 1987, The New England journal of medicine.

[11]  B. V. van Krimpen,et al.  Lysis of tumor cells by CD3+4-8-16+ T cell receptor alpha beta- clones, regulated via CD3 and CD16 activation sites, recombinant interleukin 2, and interferon beta 1. , 1987, Journal of immunology.

[12]  T. Seyama,et al.  Cryopreservation of human lymphocytes for assessment of lymphocyte subsets and natural killer cytotoxicity. , 1986, Journal of immunological methods.

[13]  S. Rosenberg,et al.  Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma. , 1985, Journal of immunology.

[14]  J. Gratama,et al.  NATURAL IMMUNITY AND GRAFT‐VERSUS‐HOST DISEASE , 1985 .

[15]  S. Rosenberg,et al.  Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2 , 1984, The Journal of experimental medicine.

[16]  P. Greenberg,et al.  Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2 , 1982, The Journal of experimental medicine.

[17]  S. Rosenberg,et al.  Lymphokine-Activated Killer Cells , 1989 .

[18]  S. Rosenberg Immunotherapy of cancer using interleukin 2: current status and future prospects. , 1988, Immunology today.

[19]  P. Hersey,et al.  'Nonspecific' MHC-unrestricted killer cells and their receptors. , 1987, Immunology today.